BASF Prepares for its 150th Anniversary in 2015
BASF is introducing a new claim “We create chemistry” in its logo. This change to the company’s brand identity underlines how BASF collaborates and innovates with customers and partners to contribute to a sustainable future. The new claim is derived from BASF’s “We create chemistry” strategy, which was announced in 2011.
“Since we launched this strategy, BASF has been increasingly focusing on offering its customers functionalised products and solutions based on chemistry as a clever combination of compounds. It is, therefore, the right time to make the next step and move from ‘The Chemical Company’ to ‘We create chemistry.’ The new claim refers not only to science but also to the chemistry between people, which is at the core of BASF and its brand,” explained Dr Kurt Bock, Chairman of the Board of Executive Directors of BASF.
Initially, “We create chemistry” will mainly be used in the logo in circumstances directly related to the company’s 150th anniversary. As of 1 January 2015, it will be applied broadly throughout BASF. The other elements of BASF’s corporate design, for example the six corporate colors, will remain unchanged.
In accordance with its company purpose “We create chemistry for a sustainable future,” BASF’s goal is to bring together people and ideas in a process of co-creation. BASF is inviting people to collaborate on developing solutions to global challenges related to urban living, smart energy and food throughout the anniversary year. To spark the discussion, the company has launched an interactive platform called Creator Space online at www.creator-space.basf.com. Here, customers, scientists, the public and BASF experts are invited to exchange thoughts and ideas.
In 2015, insights from the online conversation will form the basis for discussions at numerous live and virtual co-creation events around the world. The aim is to use the anniversary year to drive innovation and make a lasting contribution to society and BASF’s business.
“Our 150-year history shows that chemistry is an enabler for new ideas and solutions. Innovation in the 21st century will require new strategies and tools, and social networks are an important part of the mix. We invite everyone to join the conversation on Creator Space online,” said Bock.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.